<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>Novo</title>
    <link>https://www.biospace.com/employer/545568/novo</link>
    <description>Novo</description>
    <language>en-US</language>
    <lastBuildDate>Tue, 05 Dec 2017 18:54:29 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/545568/novo.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>World's Top 10 Best Biotech Companies</title>
      <link>https://www.biospace.com/unique-world-s-top-10-best-biotechs</link>
      <dc:creator>Mark Terry</dc:creator>
      <description>There are hundreds, even thousands of biotech and pharmaceutical companies.</description>
      <pubDate>Tue, 05 Dec 2017 18:54:29 GMT</pubDate>
      <guid>https://www.biospace.com/unique-world-s-top-10-best-biotechs</guid>
    </item>
    <item>
      <title>Novo Nordisk Snags FDA Approval for Oral Type 2 Diabetes Drug</title>
      <link>https://www.biospace.com/novo-nordisk-snags-fda-approval-for-oral-type-2-diabetes-drug</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>Novo Nordisk’s oral-semaglutide for type 2 diabetes snagged approval from the U.S. Food and Drug Administration late Friday, marking it as the first such treatment to be approved in pill form.</description>
      <pubDate>Mon, 23 Sep 2019 14:03:24 GMT</pubDate>
      <guid>https://www.biospace.com/novo-nordisk-snags-fda-approval-for-oral-type-2-diabetes-drug</guid>
    </item>
    <item>
      <title>Novo Nordisk Launches $99 Insulin Program</title>
      <link>https://www.biospace.com/novo-nordisk-launches-99-insulin-program</link>
      <dc:creator>Mark Terry</dc:creator>
      <description>In the My$99Insulin Program, patients can buy up to three vials or two packs of FlexPen/FlexTouch/PenFill pens of any combination of Novo Nordisk insulins for $99.</description>
      <pubDate>Thu, 02 Jan 2020 15:24:07 GMT</pubDate>
      <guid>https://www.biospace.com/novo-nordisk-launches-99-insulin-program</guid>
    </item>
    <item>
      <title>Novo Nordisk Wins FDA Approval for Mealtime Insulin Treatment for Children</title>
      <link>https://www.biospace.com/fda-approves-novo-nordisk-s-mealtime-insulin-option-for-children</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>The company said Fiasp is the “first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation.”</description>
      <pubDate>Tue, 07 Jan 2020 13:10:41 GMT</pubDate>
      <guid>https://www.biospace.com/fda-approves-novo-nordisk-s-mealtime-insulin-option-for-children</guid>
    </item>
    <item>
      <title>M&amp;A for 2019 was Big; Will 2020 Be Even Bigger?</title>
      <link>https://www.biospace.com/m-and-a-for-2019-was-big-will-2020-be-even-bigger</link>
      <dc:creator>Mark Terry</dc:creator>
      <description>Consulting firm EY released its annual report on mergers and acquisitions (M&amp;A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.</description>
      <pubDate>Mon, 13 Jan 2020 14:46:07 GMT</pubDate>
      <guid>https://www.biospace.com/m-and-a-for-2019-was-big-will-2020-be-even-bigger</guid>
    </item>
    <item>
      <title>Novo Nordisk's Ozempic Wins Approval for Reducing Cardiovascular Events in Diabetes Patients</title>
      <link>https://www.biospace.com/novo-nordisk-snags-new-indication-for-ozempic-to-reduce-mace-in-type-2-diabetes-patients</link>
      <dc:creator>Alex Keown</dc:creator>
      <description>For patients with diabetes, the new indication could become a key for survival as there is a well-established link between cardiovascular disease and type 2 diabetes.</description>
      <pubDate>Fri, 17 Jan 2020 13:15:12 GMT</pubDate>
      <guid>https://www.biospace.com/novo-nordisk-snags-new-indication-for-ozempic-to-reduce-mace-in-type-2-diabetes-patients</guid>
    </item>
    <item>
      <title>Biotech Q4 Earnings Synopsis: Major Restructuring and Overall Growth Are Themes</title>
      <link>https://www.biospace.com/q4-roundup-bristol-myers-squibb-abbvie-novo-nordisk-merck-gsk-and-sanofi</link>
      <dc:creator>Mark Terry</dc:creator>
      <description>It was a busy week for biotech quarterly and annual reports. Here’s a look at some of the top stories including Bristol-Myers Squibb, AbbVie, GSK, Merck and more.</description>
      <pubDate>Fri, 07 Feb 2020 15:11:31 GMT</pubDate>
      <guid>https://www.biospace.com/q4-roundup-bristol-myers-squibb-abbvie-novo-nordisk-merck-gsk-and-sanofi</guid>
    </item>
    <item>
      <title>Novo Nordisk launches ESPEROCT® in the U.S. for the treatment of people with hemophilia A</title>
      <link>https://www.biospace.com/novo-nordisk-launches-esperoct-in-the-u-s-for-the-treatment-of-people-with-hemophilia-a</link>
      <description>When used by adults every four days, ESPEROCT® can help reduce the frequency of bleeding with less frequent dosing</description>
      <pubDate>Tue, 11 Feb 2020 04:39:48 GMT</pubDate>
      <guid>https://www.biospace.com/novo-nordisk-launches-esperoct-in-the-u-s-for-the-treatment-of-people-with-hemophilia-a</guid>
    </item>
    <item>
      <title>Lilly and Novo Nordisk Question FDA’s Draft Guidance on Insulin Biosimilars</title>
      <link>https://www.biospace.com/lilly-and-novo-nordisk-question-fda-s-draft-guidance-on-insulin-biosimilars</link>
      <dc:creator>Mark Terry</dc:creator>
      <description>In November 2019, the U.S. Food and Drug Administration (FDA) released new draft guidance that would help generic drug companies bring biosimilars to insulin to the market more quickly. And now there are reports that two of the three primary biopharma companies that sell insulin in the U.S. are trying to change that draft guidance.</description>
      <pubDate>Wed, 12 Feb 2020 15:52:23 GMT</pubDate>
      <guid>https://www.biospace.com/lilly-and-novo-nordisk-question-fda-s-draft-guidance-on-insulin-biosimilars</guid>
    </item>
    <item>
      <title>Novo Nordisk Pauses Three Clinical Trials Because of Non-Fatal Thrombotic Events</title>
      <link>https://www.biospace.com/novo-nordisk-pauses-3-clinical-trials-because-of-non-fatal-thrombotic-events</link>
      <dc:creator>Mark Terry</dc:creator>
      <description>No more patients will be enrolled in the trials and current treatment “will cease” while they determine the risks and plans for the trials.</description>
      <pubDate>Tue, 17 Mar 2020 11:18:36 GMT</pubDate>
      <guid>https://www.biospace.com/novo-nordisk-pauses-3-clinical-trials-because-of-non-fatal-thrombotic-events</guid>
    </item>
  </channel>
</rss>
